Alyeska Investment Group L.P. Takes $25.99 Million Position in Agilent Technologies, Inc. $A

Key Points

• Alyeska Investment Group L.P. acquired approximately $25.99 million worth of Agilent Technologies shares, totaling 222,159 shares, representing a new stake in the medical research company.
• Agilent Technologies reported earnings of $1.37 per share for the last quarter, meeting analyst expectations, along with a revenue of $1.74 billion, surpassing the forecast.
• As of the latest analysis, Agilent Technologies holds a consensus price target of $139.25 with ratings ranging from "Buy" to "Hold" by six analysts.

Alyeska Investment Group L.P. acquired a new stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 222,159 shares of the medical research company's stock, valued at approximately $25,988,000. Alyeska Investment Group L.P. owned about 0.08% of Agilent Technologies as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its position in Agilent Technologies by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company's stock valued at $3,908,141,000 after acquiring an additional 240,965 shares during the last quarter. Pictet Asset Management Holding SA boosted its holdings in Agilent Technologies by 2.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company's stock valued at $624,888,000 after acquiring an additional 128,131 shares during the period. Generation Investment Management LLP boosted its holdings in Agilent Technologies by 19.8% during the 1st quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company's stock valued at $582,976,000 after acquiring an additional 824,243 shares during the period. Deutsche Bank AG boosted its holdings in Agilent Technologies by 0.9% during the 4th quarter. Deutsche Bank AG now owns 4,436,700 shares of the medical research company's stock valued at $596,026,000 after acquiring an additional 38,348 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Agilent Technologies by 9.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,231,981 shares of the medical research company's stock valued at $434,184,000 after acquiring an additional 283,445 shares during the period. Institutional investors own 87.41% of the company's stock.

Insider Activity at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the transaction, the chief executive officer directly owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.26% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Robert W. Baird boosted their price objective on Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, August 28th. UBS Group lowered their target price on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a report on Thursday, May 29th. TD Cowen upped their target price on Agilent Technologies to $150.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. JPMorgan Chase & Co. lowered their price objective on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research note on Thursday, May 29th. Finally, Leerink Partners upped their price objective on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Friday, May 30th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Agilent Technologies currently has an average rating of "Moderate Buy" and an average price target of $139.25.

Agilent Technologies Stock Down 0.4%

Shares of A traded down $0.54 during trading hours on Wednesday, hitting $125.72. The company had a trading volume of 325,348 shares, compared to its average volume of 1,949,359. The company has a market capitalization of $35.64 billion, a PE ratio of 29.50, a price-to-earnings-growth ratio of 3.99 and a beta of 1.24. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84. The company's fifty day moving average price is $119.54 and its two-hundred day moving average price is $116.07.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business's revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.